DEBT (Tables)

9 Months Ended

Jul. 31, 2024

SCHEDULE OF OUTSTANDING DEBT INSTRUMENTS

The table below presents outstanding debt instruments as of July 31, 2024 and October 31, 2023:

	July 31, 2024			October 31, 2023

Short Term
2021 Series convertible notes – related party	$	480,000		$	480,000
2024 Series Senior Secured convertible notes		4,718,750			-
Premium 2024 Series Senior Secured convertible notes		146,033			-
Total Short-Term Debt		5,344,783			480,000
Long Term
Unsecured 6% note payable – related party	$	767,288		$	767,288
Unsecured 4% note payable – related party		1,221,958			1,221,958
2022 Series convertible notes		200,000			200,000
2023 Series convertible notes – stock settled		405,000			405,000
Discount 2023 Series convertible notes		(55,153	)		(64,285	)
2023 Series B convertible notes – stock settled		1,312,600			1,312,600
Discount 2023 Series B convertible notes		(830,396	)		(891,582	)
Total Long-Term Debt		3,021,297			2,950,979
Total Debt	$	8,366,080		$	3,430,979

SCHEDULE OF FUTURE MATURITIES OUTSTANDING DEBT OBLIGATIONS

The table below presents the future maturities of outstanding debt obligations as of July 31, 2024:


Fiscal year 2024	$	5,198,750
Fiscal year 2025		-
Fiscal year 2026		1,989,246
Fiscal year 2027		200,000
Fiscal year 2028		1,717,600
Total	$	9,105,596

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Vitro Biopharma, Inc. 10-Q